140 related articles for article (PubMed ID: 8693714)
1. [Evaluation of the cardioprotective effect of bispiperazinedione ICRF-187 (Cardioxane) in patients treated with anthracyclines--an echocardiographic study].
Elbl L; Vásová I; Chaloupka V; Hájek R; Vorlícek J
Vnitr Lek; 1996 Apr; 42(4):268-73. PubMed ID: 8693714
[TBL] [Abstract][Full Text] [Related]
2. [The role of cardioxane (ICRF-187) in the prevention of cardiotoxicity of anthracyclines in the combined drug therapy of extensive ovarian cancer].
Protasov DA; Zel'dovich DR; Kuz'mina LP; Manikhas GM
Vopr Onkol; 1998; 44(6):718-21. PubMed ID: 10087973
[TBL] [Abstract][Full Text] [Related]
3. [Prevention of cardiotoxicity of doxorubicin (Adriamycin) using cardioxane (ICRF-187, dexrazoxane) in the combination chemotherapy of disseminated breast cancer].
Gershanovich ML; Moiceenko VM; Orlova RV
Vopr Onkol; 1993; 39(1-3):26-32. PubMed ID: 8073671
[TBL] [Abstract][Full Text] [Related]
4. Protective effects of cardioxane against anthracycline-induced cardiotoxicity in relapsed acute myeloid leukemias.
Lemez P; Maresová J
Neoplasma; 1996; 43(6):417-9. PubMed ID: 8996568
[TBL] [Abstract][Full Text] [Related]
5. [Monitoring cardiotoxicity of anthracyclines in children and possibilities of its prevention].
Sromová T; Strnadová V; Hrstková H
Vnitr Lek; 2002 Jul; 48(7):649-56. PubMed ID: 12197409
[TBL] [Abstract][Full Text] [Related]
6. [Damage of left ventricular function after treatment with doxorubicin in patients with malignant lymphomas].
Elbl L; Chaloupka V; Vásová I; Nehyba S; Vorlícek J; Navrátil M; Kiss I; Cíhalová M
Vnitr Lek; 2000 Nov; 46(11):768-75. PubMed ID: 15637892
[TBL] [Abstract][Full Text] [Related]
7. [Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy].
Elbl L; Vásová I; Krejcí M; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Mayer J; Vorlícek J
Vnitr Lek; 2006 Mar; 52(3):221-31. PubMed ID: 16722153
[TBL] [Abstract][Full Text] [Related]
8. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
Lipshultz SE; Rifai N; Dalton VM; Levy DE; Silverman LB; Lipsitz SR; Colan SD; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE
N Engl J Med; 2004 Jul; 351(2):145-53. PubMed ID: 15247354
[TBL] [Abstract][Full Text] [Related]
9. [An evaluation of the cardioprotective action of the preparation ICRF-187 (Cardioxane) during the treatment of breast cancer with large doses of adriamycin].
Min'kov ED; Niu-Tian-de GB; Shkhvatsabaia LV; Bagdasarov IuB; Zaĭtseva TI; Odzharova AA
Ter Arkh; 1994; 66(10):64-6. PubMed ID: 7863453
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.
Wexler LH; Andrich MP; Venzon D; Berg SL; Weaver-McClure L; Chen CC; Dilsizian V; Avila N; Jarosinski P; Balis FM; Poplack DG; Horowitz ME
J Clin Oncol; 1996 Feb; 14(2):362-72. PubMed ID: 8636745
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of cardioprotection with Cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide.
Kolaric K; Bradamante V; Cervek J; Cieslinska A; Cisarz-Filipcak E; Denisov LE; Donat D; Drosik K; Gershanovic M; Hudziec P
Oncology; 1995; 52(3):251-5. PubMed ID: 7715910
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen.
Jelić S; Radulović S; Nesković-Konstantinović Z; Kreacić M; Ristović Z; Bosnjak S; Milanović N; Vuletić L
Support Care Cancer; 1995 May; 3(3):176-82. PubMed ID: 7655778
[TBL] [Abstract][Full Text] [Related]
13. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.
Elbl L; Hrstkova H; Tomaskova I; Michalek J
Support Care Cancer; 2006 Feb; 14(2):128-36. PubMed ID: 16034614
[TBL] [Abstract][Full Text] [Related]
14. [Changes in left ventricular function during chemotherapy with doxorubicin].
Elbl L; Chaloupka V; Vásová I; Kiss I; Jancík J; Vorlícek J; Navrátil M
Vnitr Lek; 1999 Jul; 45(7):395-402. PubMed ID: 11045157
[TBL] [Abstract][Full Text] [Related]
15. [The use of Cardioxane in chemotherapy of malignant neoplasms in children].
Safonova SA; Punanov IuA; Dedukh VM; Kolygin BA
Vopr Onkol; 1997; 43(4):459-61. PubMed ID: 9381706
[TBL] [Abstract][Full Text] [Related]
16. [Preventing the cardiotoxic effects of anthracyclines with Cardioxane].
Semiglazov VF
Vopr Onkol; 1997; 43(6):569-74. PubMed ID: 9479353
[No Abstract] [Full Text] [Related]
17. Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care.
Hellmann K
Support Care Cancer; 1996 Jul; 4(4):305-7. PubMed ID: 8829310
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of left ventricular function in patients with mammary carcinoma after treatment with epidoxorubicin using a high-dose, short-term protocol].
D'Alto M; Maurea S; Basso A; Polverino W; Bianchi U; Bonelli A; Silvestro P; Salvatore M; Chiariello M
Cardiologia; 1997 Jun; 42(6):611-8. PubMed ID: 9289377
[TBL] [Abstract][Full Text] [Related]
19. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
20. [Anthracyclines and the heart].
Mazzarello GP; Morra L
Recenti Prog Med; 1998 Sep; 89(9):459-64. PubMed ID: 9796378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]